Side-by-side comparison of AI visibility scores, market position, and capabilities
Greenwood Village CO YC W20 clinical biotech (NASDAQ: VRDN) with $636.6M cash; veligrotug BLA submission H2 2025 for thyroid eye disease competing with Tepezza; FcRn inhibitor platform with VRDN-003 and VRDN-006 in development.
Viridian Therapeutics is a Greenwood Village, Colorado-based clinical-stage biotechnology company — backed by Y Combinator (W20) and publicly traded on NASDAQ (VRDN) — developing FcRn inhibitor therapies for thyroid eye disease (TED) and other serious rare diseases driven by IgG autoantibodies. Maintaining $636.6 million in cash and short-term investments as of March 2025 (sufficient to fund operations into the second half of 2027), Viridian is advancing veligrotug (subcutaneous FcRn inhibitor, BLA submission expected H2 2025 for TED, MAA to EMA expected H1 2026), VRDN-003 (topline clinical data expected H1 2026), and VRDN-006 (proof-of-concept data expected Q3 2025), with $86.6 million in R&D expenses in Q2 2025 reflecting accelerated clinical development investment.
German craftsman AI voice agent answering calls and scheduling 24/7 for 1M+ Handwerk businesses; YC-backed targeting phone automation for HVAC, plumbing, and electrical trades in Germany.
Hey Telo is a Berlin-based AI voice agent company building phone-answering and administrative automation specifically for Germany's 1 million+ independent craftsman businesses (Handwerksbetriebe) — HVAC technicians, plumbers, electricians, carpenters, and other skilled trades — who lose significant revenue daily to unanswered calls and administrative burden. A Y Combinator-backed startup, Hey Telo provides voice AI agents that answer calls professionally 24/7, schedule appointments, and provide quotes while the craftsman is on-site working.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.